Thymoglobulin

also known as rabbit antithymocyte globulin · Anti-Thymocyte Globulin (Rabbit) · rabbitATG · rATG · ATG · ATG-Fresenius · Thymoglobuline · antithymocyte globulin · +33 more

Protein / enzyme biologic

Developed for: myelodysplastic syndrome · acute myeloid leukemia · aplastic anemia · graft versus host disease · hematopoietic and lymphoid cell neoplasm · leukemia · transplant rejection · disease related to hematopoietic stem cell transplant
+47 more
· chronic myeloid leukemia · acute lymphoblastic leukemia · lymphoma · plasma cell myeloma · sickle cell disease · acquired aplastic anemia · cancer · end stage renal failure · immunodeficiency disease · liver disorder · acute graft versus host disease · bone marrow failure syndrome · chronic lymphocytic leukemia/small lymphocytic lymphoma · diabetes mellitus · hematologic disorder · Hodgkins lymphoma · kidney failure · neuroblastoma · paroxysmal nocturnal hemoglobinuria · type 1 diabetes mellitus · acquired thrombocytopenia · acute transplant rejection · anemia · autosomal genetic disease · beta thalassemia · disease of orbital part of eye adnexa · engraftment syndrome · hemophagocytic syndrome · histiocytosis · idiopathic aplastic anemia · IgA glomerulonephritis · inborn errors of metabolism · juvenile myelomonocytic leukemia · liver failure · lymphoid hemopathy · metabolic disease · myopathy · osteopetrosis · primary acquired red cell aplasia · refractory plasma cell neoplasm · relapsing-remitting multiple sclerosis · severe combined immunodeficiency · systemic sclerosis · thalassemia · Wiskott-Aldrich syndrome · impaired renal function disease · ischemic disease
Investigated by: Genzyme, a Sanofi Company · M.D. Anderson Cancer Center · Peking University People's Hospital · The Korean Society of Pediatric Hematology Oncology · Washington University School of Medicine · Columbia University
+109 more
· Institut Paoli-Calmettes · Sanofi · University of Miami · University of Nebraska · Association for Training, Education, and Research in Hematology, Immunology, and Transplantation · City of Hope Medical Center · Fresenius AG · Institute of Hematology & Blood Diseases Hospital, China · Masonic Cancer Center, University of Minnesota · Nantes University Hospital · National Institute of Allergy and Infectious Diseases (NIAID) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Neovii Biotech · Novartis · St. Jude Children's Research Hospital · The Cleveland Clinic · University of Cincinnati · medac GmbH · Agence de La Biomédecine · Alberta Health services · Amgen · Ann & Robert H Lurie Children's Hospital of Chicago · Astellas Pharma Inc · Barbara Ann Karmanos Cancer Institute · Belgian Hematological Society · Brigham and Women's Hospital · California Institute for Regenerative Medicine (CIRM) · Canadian Institutes of Health Research (CIHR) · Children's Discovery Institute · Children's Hospital Medical Center, Cincinnati · Chinese PLA General Hospital · Clinical Trials in Organ Transplantation · Coordinación de Investigación en Salud, Mexico · Emory University · European Society for Blood and Marrow Transplantation · Fondazione IRCCS Policlinico San Matteo di Pavia · Franco Locatelli · Fred Hutchinson Cancer Center · Fujian Medical University · Georgetown University · Hadassah Medical Organization · Hoffmann-La Roche · Hospices Civils de Lyon · Hospital Clinic of Barcelona · Hospital Geral de Fortaleza · Hospital de Santa Maria, Portugal · Hospital do Rim e Hipertensão · Institut Klinické a Experimentální Medicíny · Institute for Clinical and Experimental Medicine · Instituto de Investigación Hospital Universitario La Paz · Italian Association for Pediatric Hematology Oncology · Johns Hopkins University · King Faisal Specialist Hospital & Research Center · King's College Hospital NHS Trust · Lahey Clinic · McMaster University · Medical University of Silesia · Millennium Pharmaceuticals, Inc. · Ministry of Health, Czech Republic · Ministry of Health, France · Nagoya University · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · National Institute of Blood Disease Center, Pakistan · New York Medical College · Northwestern University · Otsuka America Pharmaceutical · Peking Union Medical College Hospital · Pfizer · Prof. Dr. Petra Reinke · Prof. Dr. med. Wolfgang Bethge · Providence Health & Services · Rising Tide Foundation · all 115 on the full record

Trials 113 · started per year

today

20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT04776850	Dec 2020 → Dec 2022	beta-thalassemia major, sickle cell disease, sickle cell-beta plus-thalassemia, sickle cell-beta zero-thalassemia	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded
Phase 17 trials
Phase 1	NCT07052370	Sep 2025 → Dec 2028 expected	hematopoietic and lymphoid system neoplasm	St. Jude Children's Research Hospital	Recruiting	No outcome recorded
Phase 1	NCT03249831	Jan 2019 → Jan 2027 expected	sickle cell disease, thalassemia	City of Hope Medical Center	Active not recruiting	No outcome recorded
Phase 1	NCT00545519	Oct 2006 → Mar 2008	refractory plasma cell neoplasm	Washington University School of Medicine	Completed	No outcome recorded
Phase 1	NCT00317798	Apr 2006 → Apr 2011	plasma cell myeloma, poisoning	University of Rochester	Completed	No outcome recorded
Phase 1	NCT00278564	Sep 2005 → Jul 2016	myopathy	Northwestern University	Terminated	No outcome recorded
Phase 1	NCT00670410	Nov 2003 → Dec 2010	neuroblastoma	Columbia University	Terminated	No outcome recorded
Phase 1	NCT00040651	Jul 2002 → Mar 2007	systemic sclerosis	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Terminated	No outcome recorded
Phase 1/28 trials
Phase 1/2	NCT06158828	Nov 2024 → Sep 2028 expected	acute myeloid leukemia by FAB classification, childhood acute myeloid leukemia	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 1/2	NCT01106157	Apr 2010 → Jan 2015	type 1 diabetes mellitus	University of Florida	Completed	No outcome recorded
Phase 1/2	NCT00679536	May 2008 → May 2015	leukemia	Ann & Robert H Lurie Children's Hospital of Chicago	Unknown	No outcome recorded
Phase 1/2	NCT00801931	Sep 2007 → May 2009	anemia, immunodeficiency disease, leukemia, lymphoma +1	Columbia University	Terminated	No outcome recorded
Phase 1/2	NCT00885833	Feb 2007 → Mar 2012	Wiskott-Aldrich syndrome	The Korean Society of Pediatric Hematology Oncology	Completed	No outcome recorded
Phase 1/2	NCT00409695	Dec 2006 → Aug 2007	acute graft versus host disease	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 1/2	NCT00887042	Jun 2006 → May 2012	acute myeloid leukemia	The Korean Society of Pediatric Hematology Oncology	Unknown	No outcome recorded
Phase 1/2	NCT00448357	Oct 2005 → Nov 2015	leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm	UNC Lineberger Comprehensive Cancer Center	Completed	No outcome recorded
Phase 249 trials
Phase 2	NCT07677306	Jul 2026 → Dec 2027 expected	myelodysplastic syndrome	Peking University People's Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT06769568	Jan 2025 → Sep 2028 expected	aplastic anemia, disease related to hematopoietic stem cell transplant	Institute of Hematology & Blood Diseases Hospital, China	Not yet recruiting	No outcome recorded
Phase 2	NCT06872333	Nov 2024 → Jun 2030 expected	disease related to hematopoietic stem cell transplant, sickle cell disease	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT06412497	Jun 2024 → May 2035 expected	acquired thrombocytopenia, idiopathic aplastic anemia, paroxysmal nocturnal hemoglobinuria, primary acquired red cell aplasia	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT06066255	Mar 2024 → Mar 2026	hematopoietic and lymphoid cell neoplasm	Institut Paoli-Calmettes	Unknown	No outcome recorded
Phase 2	NCT05293509	Mar 2022 → Sep 2023	disease related to hematopoietic stem cell transplant	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded
Phase 2	NCT03980769	May 2021 → Jul 2028 expected	hematologic disorder	Fred Hutchinson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT04395222	Oct 2020 → Sep 2022 overdue	hematopoietic and lymphoid cell neoplasm	Weill Medical College of Cornell University	Active not recruiting	No outcome recorded
Phase 2	NCT03852407	Feb 2019 → Nov 2033 expected	Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +2	University of Liege	Recruiting	No outcome recorded
Phase 2	NCT05214066	Feb 2019 → Aug 2022	acute graft versus host disease, chronic graft versus host disease	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 2	NCT04114188	Dec 2016 → Dec 2020	transplant rejection	Prof. Dr. Petra Reinke	Completed	No outcome recorded
Phase 2	NCT02877082	Sep 2016 → Jul 2017	chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia, diffuse large B-cell lymphoma, follicular lymphoma +5	Emory University	Terminated	No outcome recorded
Phase 2	NCT02544113	Dec 2015 → Jun 2018	liver failure	The Cleveland Clinic	Completed	No outcome recorded
Phase 2	NCT02627573	Jul 2015 → Apr 2019	atypical chronic myeloid leukemia, BCR-ABL1 negative, chronic myeloid leukemia, myelodysplastic syndrome	St. Petersburg State Pavlov Medical University	Terminated	No outcome recorded
Phase 2	NCT02483325	Sep 2014 → Mar 2018	hematologic disorder	Institut Paoli-Calmettes	Completed	No outcome recorded
Phase 2	NCT02203396	Aug 2014 → Sep 2016	aplastic anemia	Institute of Hematology & Blood Diseases Hospital, China	Completed	No outcome recorded
Phase 2	NCT01994824	Jan 2014 → Jun 2017	graft versus host disease	University of Calgary	Terminated	No outcome recorded
Phase 2	NCT01856257	Jul 2013 → Apr 2016	—	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT01556347	Jul 2012 → May 2016	—	Providence Health & Services	Terminated	No outcome recorded
Phase 2	NCT01582048	Apr 2012 → Aug 2016	disease related to hematopoietic stem cell transplant	Prof. Dr. med. Wolfgang Bethge	Terminated	No outcome recorded
Phase 2	NCT01572181	Apr 2012 → Oct 2017	hematopoietic and lymphoid cell neoplasm	Nantes University Hospital	Completed	No outcome recorded
Phase 2	NCT01566656	Mar 2012 → Nov 2016	hematopoietic and lymphoid cell neoplasm	Nantes University Hospital	Completed	No outcome recorded
Phase 2	NCT01810926	Sep 2011 → Aug 2015	graft versus host disease	Franco Locatelli	Unknown	No outcome recorded
Phase 2	NCT01049854	Sep 2011 → Nov 2017	beta thalassemia, bone marrow failure syndrome, histiocytosis, immunodeficiency disease +4	New York Medical College	Completed	No outcome recorded
Phase 2	NCT01246206	Nov 2010 → Oct 2013	hematopoietic and lymphoid cell neoplasm	Barbara Ann Karmanos Cancer Institute	Completed	No outcome recorded
Phase 2	NCT01939171	Jun 2010 → Feb 2012	—	Instituto de Investigación Hospital Universitario La Paz	Completed	No outcome recorded
Phase 2	NCT01104025	Apr 2010 → Nov 2015	hemophagocytic syndrome	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 2	NCT00906204	Mar 2010 → Jul 2014	end stage renal failure, kidney failure	Wright State University	Completed	No outcome recorded
Phase 2	NCT01135537	Nov 2009 → Jan 2014	autosomal genetic disease, cancer, metabolic disease	The Hospital for Sick Children	Terminated	No outcome recorded
Phase 2	NCT00882323	Nov 2008 → Oct 2012	aplastic anemia	The Korean Society of Pediatric Hematology Oncology	Unknown	No outcome recorded
Phase 2	NCT00471848	Aug 2008 → Oct 2011	acquired aplastic anemia	European Society for Blood and Marrow Transplantation	Completed	No outcome recorded
Phase 2	NCT00709592	Jul 2008 → Feb 2014	Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +2	Virginia Commonwealth University	Completed	No outcome recorded
Phase 2	NCT01530555	Apr 2008 → Jul 2013	acquired aplastic anemia	King Faisal Specialist Hospital & Research Center	Completed	No outcome recorded
Phase 2	NCT00593645	Nov 2007 → Dec 2008	acute myeloid leukemia, myelodysplastic syndrome	Washington University School of Medicine	Terminated	No outcome recorded
Phase 2	NCT00542828	Oct 2007 → May 2009	myelodysplastic syndrome	Genzyme, a Sanofi Company	Terminated	No outcome recorded
Phase 2	NCT00915811	Jun 2007 → Jun 2011	acute myeloid leukemia, myelodysplastic syndrome	King's College Hospital NHS Trust	Terminated	No outcome recorded
Phase 2	NCT00750126	Apr 2007 → Apr 2009	cancer, hematopoietic and lymphoid cell neoplasm	University Hospital, Clermont-Ferrand	Unknown	No outcome recorded
Phase 2	NCT00506948	Sep 2006 → Oct 2010	leukemia, lymphoma, myelodysplastic syndrome	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00436722	Jun 2006 → Jul 2009	liver disorder	Hospital Clinic of Barcelona	Terminated	No outcome recorded
Phase 2	NCT00475020	Jan 2006 → Oct 2017	myelofibrosis	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00737685	Jan 2006 → Aug 2012	aplastic anemia	The Korean Society of Pediatric Hematology Oncology	Unknown	No outcome recorded
Phase 2	NCT00260689	Nov 2005 → May 2016	neutropenia, pancytopenia, thrombocytopenia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00806598	May 2005 → Jun 2012	aplastic anemia, myelodysplastic syndrome	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00117689	Apr 2005 → Dec 2007	liver disorder, transplant rejection	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00062712	Jun 2003 → Mar 2007	—	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 2	NCT00089947	Jun 2003 → Dec 2005	transplant rejection	Genzyme, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00894049	Nov 2002 → Feb 2013	cancer, disease related to hematopoietic stem cell transplant, hematopoietic and lymphoid cell neoplasm	Institut Paoli-Calmettes	Completed	No outcome recorded
Phase 2	NCT00006178	Aug 2000 → Dec 2007	kidney failure	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 2	NCT00235300	May 2000 → Apr 2003	acute transplant rejection	Genzyme, a Sanofi Company	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT03793517	Sep 2018 → Oct 2023 overdue	acute myeloid leukemia, disease related to hematopoietic stem cell transplant	Peking University People's Hospital	Recruiting	No outcome recorded
Phase 2/3	NCT03631563	Mar 2013 → Dec 2018	graft versus host disease	Fujian Medical University	Unknown	No outcome recorded
Phase 2/3	NCT01019876	Sep 2002 → Sep 2021	Fanconi anemia, bone marrow failure syndrome, osteopetrosis, severe combined immunodeficiency	Columbia University	Completed	No outcome recorded
Phase 310 trials
Phase 3	NCT05385432	Nov 2023 → Dec 2030 expected	transplant rejection	University Hospital, Tours	Recruiting	No outcome recorded
Phase 3	NCT01844635	May 2012 → May 2016	acquired aplastic anemia	Nagoya University	Unknown	No outcome recorded
Phase 3	NCT01217723	Apr 2010 → Jan 2014	hematopoietic and lymphoid system neoplasm	McMaster University	Unknown	No outcome recorded
Phase 3	NCT01028092	Mar 2009 → Mar 2014	—	University Hospital, Brest	Completed	No outcome recorded
Phase 3	NCT00934557	Mar 2008 → ?	—	Fondazione IRCCS Policlinico San Matteo di Pavia	Unknown	No outcome recorded
Phase 3	NCT00275509	Jan 2007 → Jun 2010	chronic renal failure syndrome	Johns Hopkins University	Completed	No outcome recorded
Phase 3	NCT00678275	Oct 2006 → Feb 2014	acute lymphoblastic leukemia, acute myeloid leukemia	University Medical Center Hamburg-Eppendorf	Completed	No outcome recorded
Phase 3	NCT00130754	Feb 2005 → Nov 2007	graft versus host disease	Hadassah Medical Organization	Completed	No outcome recorded
Phase 3	NCT00655343	Feb 2003 → Mar 2007	graft versus host disease	Neovii Biotech	Completed	No outcome recorded
Phase 3	NCT00186823	Mar 2002 → Sep 2005	acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia +2	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 419 trials
Phase 4	NCT05743400	Sep 2023 → Apr 2025 overdue	thrombotic microangiopathy	Hospices Civils de Lyon	Recruiting	No outcome recorded
Phase 4	NCT06009965	Jan 2023 → Jan 2025	aplastic anemia	Peking Union Medical College Hospital	Unknown	No outcome recorded
Phase 4	NCT03099122	Aug 2017 → Nov 2019	end stage renal failure	Sanofi	Completed	No outcome recorded
Phase 4	NCT03006419	Dec 2016 → Jul 2019	transplant rejection	Coordinación de Investigación en Salud, Mexico	Completed	No outcome recorded
Phase 4	NCT03088280	Jun 2015 → Jan 2018	—	Hospital Geral de Fortaleza	Unknown	No outcome recorded
Phase 4	NCT01856803	Oct 2013 → Jun 2018	graft versus host disease	Peking University People's Hospital	Completed	No outcome recorded
Phase 4	NCT02083991	Jan 2013 → Jan 2017	diabetes mellitus	Vastra Gotaland Region	Completed	No outcome recorded
Phase 4	NCT01729494	Sep 2012 → Dec 2018	—	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT01354301	May 2011 → Apr 2014	cytomegalovirus infection, transplant rejection	Hospital do Rim e Hipertensão	Completed	No outcome recorded
Phase 4	NCT02523768	Jan 2011 → Jan 2020	IgA glomerulonephritis	University Hospital of Saint-Etienne	Terminated	No outcome recorded
Phase 4	NCT01149993	Jun 2010 → Jun 2012	—	Georgetown University	Withdrawn	No outcome recorded
Phase 4	NCT00861536	Jan 2009 → Feb 2015	—	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 4	NCT00782821	Sep 2008 → Feb 2013	—	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT00706680	Feb 2008 → Feb 2009	diabetes mellitus, transplant rejection	University Health Network, Toronto	Unknown	No outcome recorded
Phase 4	NCT00564538	Dec 2007 → Dec 2009	liver disorder	University of Nebraska	Unknown	No outcome recorded
Phase 4	NCT01172418	Feb 2006 → May 2010	—	University of Miami	Completed	No outcome recorded
Phase 4	NCT00556933	Apr 2004 → Apr 2011	end stage renal failure	University of Nebraska	Completed	No outcome recorded
Phase 4	NCT00685061	Nov 2002 → Sep 2004	—	University of Miami	Completed	No outcome recorded
Phase 4	NCT00681343	Sep 2002 → Oct 2006	—	University of Miami	Completed	No outcome recorded

Phase not applicable16 trials
—	NCT05482542	Jan 2023 → Jul 2027	relapsing-remitting multiple sclerosis	Scripps Health	Withdrawn	No outcome recorded
—	NCT05199103	Jan 2020 → Dec 2023	disease of orbital part of eye adnexa	Medical University of Silesia	Unknown	No outcome recorded
—	NCT03821987	Dec 2018 → Dec 2021	aplastic anemia, engraftment syndrome	Peking University People's Hospital	Unknown	No outcome recorded
—	NCT03035422	Jan 2018 → Dec 2021	acute myeloid leukemia	Association for Training, Education, and Research in Hematology, Immunology, and Transplantation	Completed	No outcome recorded
—	NCT03079089	Jun 2017 → Sep 2023	lymphoid hemopathy	Association for Training, Education, and Research in Hematology, Immunology, and Transplantation	Completed	No outcome recorded
—	NCT02028416	Sep 2013 → Dec 2017	aplastic anemia	National Institute of Blood Disease Center, Pakistan	Unknown	No outcome recorded
—	NCT01280617	Oct 2010 → Nov 2013	acute kidney injury	Lahey Clinic	Completed	No outcome recorded
—	NCT01129323	Nov 2009 → Sep 2011	aplastic anemia	City of Hope Medical Center	Withdrawn	No outcome recorded
—	NCT00970073	Aug 2009 → Jun 2015	—	The Cleveland Clinic	Completed	No outcome recorded
—	NCT00714480	Jul 2008 → Dec 2009	immunodeficiency disease	Swedish Medical Center	Completed	No outcome recorded
—	NCT00943800	Oct 2006 → Sep 2018	leukemia, myelodysplastic syndrome, plasma cell myeloma	University of Chicago	Completed	No outcome recorded
—	NCT00476229	Jun 2006 → May 2009	leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
—	NCT00235781	Jan → Feb 2006	—	Washington University School of Medicine	Terminated	No outcome recorded
—	NCT00088543	Mar 2004 → Apr 2006	acute lymphoblastic leukemia, acute myeloid leukemia, graft versus host disease	Genzyme, a Sanofi Company	Completed	No outcome recorded
—	NCT00190502	Nov 2000 → Dec 2007	type 1 diabetes mellitus	Institute for Clinical and Experimental Medicine	Unknown	No outcome recorded
—	NCT00007787	Apr 2000 → Mar 2004	chronic transplant rejection	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Also used as a comparator or background therapy in 139 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 119 trials
Phase 1	NCT07257419 Background	Aug 2026 → Dec 2031 expected	childhood acute lymphoblastic leukemia, disease related to hematopoietic stem cell transplant	St. Jude Children's Research Hospital	Recruiting	No outcome recorded
Phase 1	NCT05525507 Background	Dec 2022 → Dec 2026 expected	chronic transplant rejection, end stage renal failure	University of California, Los Angeles	Recruiting	No outcome recorded
Phase 1	NCT05298358 Background	Nov 2022 → Nov 2024	systemic sclerosis	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Terminated	No outcome recorded
Phase 1	NCT04521946 Background	Jan 2021 → Dec 2022	anaplastic ependymoma, atypical teratoid rhabdoid tumor, central nervous system germ cell tumor, choroid plexus carcinoma +3	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded
Phase 1	NCT03531736 Background	May 2018 → May 2026 overdue	myeloid hemopathy	Memorial Sloan Kettering Cancer Center	Active not recruiting	No outcome recorded
Phase 1	NCT02512497 Background	Dec 2017 → Oct 2023	T-cell large granular lymphocyte leukemia, T-cell prolymphocytic leukemia, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma	Ohio State University Comprehensive Cancer Center	Completed	No outcome recorded
Phase 1	NCT02916979 Background	Sep 2016 → Jun 2019	Waldenstrom macroglobulinemia, lymphoid leukemia, myelodysplastic syndrome, myelofibrosis +2	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
Phase 1	NCT02867800 Background	Jul 2016 → Dec 2021	graft versus host disease, sickle cell disease	Monica Bhatia	Completed	No outcome recorded
Phase 1	NCT02165007 Background	Jan 2015 → Jan 2024	sickle cell-beta-thalassemia disease syndrome, thalassemia	Catherine Bollard	Completed	No outcome recorded
Phase 1	NCT02188719 Background	Dec 2014 → Jun 2019	—	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 1	NCT02472392 Comparator	Apr 2013 → Dec 2016	Ewing sarcoma	University of Louisville	Completed	No outcome recorded
Phase 1	NCT03393611 Background	Nov 2012 → Aug 2021	acute myeloid leukemia, myelodysplastic syndrome	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 1	NCT01455506 Background	May 2009 → Dec 2013	acute myeloid leukemia, myelodysplastic syndrome	Hackensack Meridian Health	Completed	No outcome recorded
Phase 1	NCT00849888 Background	Apr 2008 → Feb 2011	DiGeorge syndrome	Sumitomo Pharma Switzerland GmbH	Terminated	No outcome recorded
Phase 1	NCT00402558 Background	May 2006 → Apr 2014	leukemia, myelodysplastic syndrome	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT00325741 Background	Jun 2004 → Oct 2015	systemic lupus erythematosus	Stanford University	Terminated	No outcome recorded
Phase 1	NCT00669890 Background	May 2004 → Dec 2012	acute myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome	New York Medical College	Terminated	No outcome recorded
Phase 1	NCT00579709 Background	Jul 2002 → Dec 2006	DiGeorge syndrome	Sumitomo Pharma Switzerland GmbH	Completed	No outcome recorded
Phase 1	NCT00424489 Background	Feb 2002 → Jun 2016	myasthenia gravis	Northwestern University	Terminated	No outcome recorded

Phase 1/210 trials
Phase 1/2	NCT07607197 Background	Feb 2024 → May 2027 expected	anti-HLA hyperimmunization, end stage renal failure	Hospital Universitari Vall d'Hebron Research Institute	Recruiting	No outcome recorded
Phase 1/2	NCT03597594 Comparator	Sep 2021 → Jul 2027 expected	severe combined immunodeficiency	St. Jude Children's Research Hospital	Active not recruiting	No outcome recorded
Phase 1/2	NCT04083183 Background	Jun 2020 → Jan 2028 expected	benign neoplasm	Fred Hutchinson Cancer Center	Recruiting	No outcome recorded
Phase 1/2	NCT04066114 Background	Dec 2019 → Sep 2023	disease related to solid organ transplantation	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT04224558 Background	Nov 2019 → Sep 2027 expected	Crohn disease	Cedars-Sinai Medical Center	Recruiting	No outcome recorded
Phase 1/2	NCT02080195 Background	Sep 2016 → Mar 2017	graft versus host disease, lupus erythematosus	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Terminated	No outcome recorded
Phase 1/2	NCT02166177 Background	Jun 2014 → Jan 2018	liver failure	Guy's and St Thomas' NHS Foundation Trust	Completed	No outcome recorded
Phase 1/2	NCT01050764 Background	Jun 2009 → Aug 2012	B-cell chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome	Everett Meyer	Terminated	No outcome recorded
Phase 1/2	NCT00579527 Background	Dec 2005 → Dec 2011	DiGeorge syndrome	Sumitomo Pharma Switzerland GmbH	Completed	No outcome recorded
Phase 1/2	NCT00303667 Background	Jan 2005 → Mar 2011	acute myeloid leukemia	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded

Phase 260 trials
Phase 2	NCT07508787 Comparator	Jun 2026 → Mar 2028 expected	transplant rejection	Nefro Avillion Clinical Development, LLC	Recruiting	No outcome recorded
Phase 2	NCT07570745 Background	May 2026 → May 2028 expected	acute graft versus host disease	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Recruiting	No outcome recorded
Phase 2	NCT06646497 Background	Jan 2025 → Jan 2030 expected	acquired aplastic anemia	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 2	NCT05735717 Background	May 2023 → Nov 2027 expected	CBL-related disorder, acute lymphoblastic leukemia, acute myeloid leukemia, central nervous system leukemia +6	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT05736419 Background	Feb 2023 → Feb 2027 expected	beta thalassemia, sickle cell disease	Memorial Sloan Kettering Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT04903054 Background	Jan → Sep 2022	disease related to solid organ transplantation	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded
Phase 2	NCT04888741 Comparator	Feb 2021 → Aug 2027 expected	Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +4	University of Birmingham	Recruiting	No outcome recorded
Phase 2	NCT04688021 Background	Dec 2020 → Dec 2024	graft versus host disease, leukemia	Yi Luo	Unknown	No outcome recorded
Phase 2	NCT04328727 Background	Nov 2020 → Jun 2022	aplastic anemia	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT04202835 Background	Oct 2020 → May 2024 overdue	acute leukemia, chronic graft versus host disease, myelodysplastic syndrome	McMaster University	Active not recruiting	No outcome recorded
Phase 2	NCT04530487 Background	Aug 2020 → Aug 2024	Ewing sarcoma/peripheral primitive neuroectodermal tumor, desmoplastic small round cell tumor, malignant peripheral nerve sheath tumor, neuroblastoma +2	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT04046549 Background	Oct 2019 → Jul 2022	transplant rejection	Amgen	Completed	No outcome recorded
Phase 2	NCT03849651 Background	Jan 2019 → Aug 2024 overdue	Hodgkins lymphoma, T-cell and NK-cell neoplasm, acute lymphoblastic leukemia, acute myeloid leukemia +3	St. Jude Children's Research Hospital	Active not recruiting	No outcome recorded
Phase 2	NCT03663335 Background	Nov 2018 → Oct 2021	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT03292861 Comparator	Sep 2018 → Mar 2026 overdue	—	Cedars-Sinai Medical Center	Enrolling by invitation	No outcome recorded
Phase 2	NCT03357159 Background	Sep 2018 → Dec 2024	graft versus host disease	Sheba Medical Center	Unknown	No outcome recorded
Phase 2	NCT03615144 Comparator	Jul 2018 → Nov 2020	hematologic disorder	Memorial Sloan Kettering Cancer Center	Terminated	No outcome recorded
Phase 2	NCT03600909 Background	May 2018 → Apr 2021	Fanconi anemia, acute myeloid leukemia, myelodysplastic syndrome	Memorial Sloan Kettering Cancer Center	Terminated	No outcome recorded
Phase 2	NCT03219359 Background	Feb 2018 → Oct 2028 expected	Crohn disease	Aaron Etra	Recruiting	No outcome recorded
Phase 2	NCT03263559 Background	Oct 2017 → Jan 2025	sickle cell disease	Medical College of Wisconsin	Completed	No outcome recorded
Phase 2	NCT02464878 Background	Jan 2017 → Nov 2022	type 1 diabetes mellitus	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT02828592 Background	Sep 2016 → Aug 2027 expected	aplastic anemia	Northside Hospital, Inc.	Recruiting	No outcome recorded
Phase 2	NCT02833805 Background	Sep 2016 → Jul 2021	aplastic anemia, bone marrow failure syndrome	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 2	NCT02790515 Background	Jul 2016 → Jul 2025 overdue	acute lymphoblastic leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome +1	St. Jude Children's Research Hospital	Active not recruiting	No outcome recorded
Phase 2	NCT02776202 Background	May 2016 → Dec 2019	sickle cell disease	National Guard Health Affairs	Unknown	No outcome recorded
Phase 2	NCT02582775 Background	Mar 2016 → Nov 2022	epidermolysis bullosa	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
Phase 2	NCT02137239 Background	Dec 2015 → May 2019	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 2	NCT02495077 Background	Nov 2015 → Jul 2021	—	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT02441803 Background	Sep 2015 → Sep 2020	leukemia	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT02404025 Background	May 2015 → Jul 2016	aplastic anemia	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT02224872 Background	Aug 2014 → Dec 2021	aplastic anemia, bone marrow failure syndrome	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 2	NCT02143830 Background	Apr 2014 → Dec 2026 expected	Fanconi anemia, acute myeloid leukemia, bone marrow failure syndrome, myelodysplastic syndrome	Children's Hospital Medical Center, Cincinnati	Recruiting	No outcome recorded
Phase 2	NCT01790594 Background	Feb 2013 → Aug 2016	—	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT01490723 Background	Jan 2013 → Apr 2019	leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT01745913 Background	Oct 2012 → Apr 2015	Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome	Weill Medical College of Cornell University	Terminated	No outcome recorded
Phase 2	NCT01810588 Background	Oct 2012 → Aug 2023 overdue	hematopoietic and lymphoid cell neoplasm	Weill Medical College of Cornell University	Active not recruiting	No outcome recorded
Phase 2	NCT01621477 Background	Aug 2012 → Dec 2015	acute lymphoblastic leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome +1	St. Jude Children's Research Hospital	Terminated	No outcome recorded
Phase 2	NCT01565616 Background	Mar 2012 → Jun 2016	sickle cell disease	Emory University	Completed	No outcome recorded
Phase 2	NCT01622556 Background	Jan 2012 → Feb 2014	hematopoietic and lymphoid system neoplasm	University of Virginia	Terminated	No outcome recorded
Phase 2	NCT01461837 Background	Jan 2012 → Dec 2025 overdue	sickle cell disease	New York Medical College	Active not recruiting	No outcome recorded
Phase 2	NCT01392989 Background	Mar 2011 → Jun 2016	anemia, myelodysplastic syndrome, myeloid leukemia, neural tube defect	Everett Meyer	Completed	No outcome recorded
Phase 2	NCT01517984 Background	Nov 2010 → May 2015	disease related to solid organ transplantation	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT00990249 Background	Oct 2009 → May 2016	acute lymphoblastic leukemia	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00916045 Background	Sep 2009 → Mar 2012	Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, myelodysplastic syndrome	King's College Hospital NHS Trust	Terminated	No outcome recorded
Phase 2	NCT00961142 Background	Jun 2009 → Dec 2015	acute lymphoblastic leukemia, acute myeloid leukemia	University Hospital Tuebingen	Terminated	No outcome recorded
Phase 2	NCT00899431 Comparator	May 2009 → Oct 2018	B-cell chronic lymphocytic leukemia	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00899847 Background	May 2009 → Apr 2014	plasma cell myeloma	Stanford University	Completed	No outcome recorded
Phase 2	NCT00857389 Background	Mar 2009 → Mar 2019	disease related to hematopoietic stem cell transplant, leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00841724 Comparator	Jan 2009 → Jan 2012	hematopoietic and lymphoid cell neoplasm	Nantes University Hospital	Completed	No outcome recorded
Phase 2	NCT00813124 Background	Dec 2008 → Sep 2014	disease related to hematopoietic stem cell transplant, leukemia	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00771875 Comparator	Sep 2008 → Dec 2012	transplant rejection	University of Cincinnati	Completed	No outcome recorded
Phase 2	NCT00566696 Background	Dec 2007 → Jan 2016	Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +3	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 2	NCT00593554 Background	Aug 2007 → Aug 2016	acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome	Sherif S. Farag	Terminated	No outcome recorded
Phase 2	NCT00523809 Background	Aug 2007 → Oct 2011	breast cancer, ovarian cancer	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00455013 Background	Jul 2007 → Oct 2008	disease related to solid organ transplantation	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 2	NCT00469014 Background	Sep 2006 → Mar 2013	acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00230035 Comparator	Sep 2005 → ?	systemic lupus erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded
Phase 2	NCT00186628 Background	Jun 2005 → Nov 2010	mantle cell lymphoma, mast cell leukemia	Stanford University	Completed	No outcome recorded
Phase 2	NCT00506129 Background	Sep 2003 → Jun 2015	disease related to hematopoietic stem cell transplant, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00038857 Background	Sep 2001 → Jun 2009	leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT07412470 Background	Mar 2026 → Aug 2029 expected	transplant rejection	Sanofi	Recruiting	No outcome recorded
Phase 2/3	NCT03799224 Background	Dec 2018 → Dec 2021	acute leukemia, disease related to hematopoietic stem cell transplant	Peking University People's Hospital	Unknown	No outcome recorded
Phase 2/3	NCT01087398 Background	Sep 2009 → Nov 2012	osteopetrosis	Tehran University of Medical Sciences	Unknown	No outcome recorded
Phase 315 trials
Phase 3	NCT06083129 Comparator	Nov 2023 → Nov 2028 expected	graft versus host disease	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 3	NCT05457556 Background	Mar 2023 → Jun 2026 overdue	acute lymphoblastic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome	Children's Oncology Group	Active not recruiting	No outcome recorded
Phase 3	NCT05600426 Comparator	Jan 2023 → Dec 2029 expected	aplastic anemia	Boston Children's Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT04547049 Comparator	Sep 2020 → Apr 2026 overdue	leukemia, myelodysplastic syndrome	First Affiliated Hospital of Zhejiang University	Active not recruiting	No outcome recorded
Phase 3	NCT04302805 Comparator	Jul 2020 → Apr 2024	—	Institute for Clinical and Experimental Medicine	Completed	No outcome recorded
Phase 3	NCT01471444 Background	Nov 2011 → Dec 2020	disease related to hematopoietic stem cell transplant, leukemia	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 3	NCT01157949 Comparator	Nov 2010 → Nov 2013	—	Cedars-Sinai Medical Center	Withdrawn	No outcome recorded
Phase 3	NCT01145976 Background	Mar 2010 → Feb 2015	aplastic anemia	Cooperative Study Group A for Hematology	Unknown	No outcome recorded
Phase 3	NCT00733733 Comparator	Jan 2008 → Jan 2010	—	Radboud University Medical Center	Unknown	No outcome recorded
Phase 3	NCT01324934 Comparator	Oct 2006 → Jan 2011	transplant rejection	Neovii Biotech	Terminated	No outcome recorded
Phase 3	NCT00316810 Comparator	Apr 2006 → Feb 2011	—	Dr. Claudia Bösmüller	Completed	No outcome recorded
Phase 3	NCT00592306 Comparator	Jan 2006 → Sep 2009	—	University of California, Los Angeles	Withdrawn	No outcome recorded
Phase 3	NCT00105183 Comparator	Jan 2005 → Jan 2010	bronchiectasis, cystic fibrosis, idiopathic pulmonary fibrosis, vascular disorder	Neovii Biotech	Completed	No outcome recorded
Phase 3	NCT00774527 Comparator	Mar 2003 → Feb 2010	bone marrow failure syndrome	Cooperative Study Group A for Hematology	Completed	No outcome recorded
Phase 3	NCT00682292 Comparator	May 2001 → Nov 2006	—	University Hospital, Lille	Completed	No outcome recorded

Phase 427 trials
Phase 4	NCT07203664 Background	Oct 2025 → Dec 2026 expected	—	Hospital Universitario La Paz	Not yet recruiting	No outcome recorded
Phase 4	NCT05634915 Comparator	Dec 2022 → Dec 2024	acute leukemia, disease related to hematopoietic stem cell transplant	The First Affiliated Hospital of Soochow University	Unknown	No outcome recorded
Phase 4	NCT04849533 Background	Apr 2021 → Jul 2023	transplant rejection	University of Cincinnati	Unknown	No outcome recorded
Phase 4	NCT04009525 Background	Jul 2019 → Jul 2023	beta-thalassemia major	First Affiliated Hospital of Guangxi Medical University	Completed	No outcome recorded
Phase 4	NCT03828682 Background	Jun 2019 → Jul 2021	immunodeficiency disease	Simon Tremblay, PharmD, PhD	Unknown	No outcome recorded
Phase 4	NCT03789006 Comparator	Mar 2018 → Mar 2022	transplant rejection	University of Khartoum	Unknown	No outcome recorded
Phase 4	NCT03470961 Comparator	Mar 2018 → Mar 2021	diabetes mellitus, end stage renal failure	Tianjin First Central Hospital	Unknown	No outcome recorded
Phase 4	NCT03171831 Background	Apr 2017 → Dec 2021	beta-thalassemia major	First Affiliated Hospital of Guangxi Medical University	Unknown	No outcome recorded
Phase 4	NCT02838992 Background	Feb 2017 → Dec 2018	aplastic anemia	Jinan Military General Hospital	Unknown	No outcome recorded
Phase 4	NCT02784561 Background	Jul 2016 → Jul 2019	leukemia	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 4	NCT02745717 Background	Jan 2016 → Dec 2021	aplastic anemia	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 4	NCT02447822 Comparator	Jun 2015 → May 2018	kidney failure	Asan Medical Center	Unknown	No outcome recorded
Phase 4	NCT02130817 Background	Sep 2014 → Oct 2015	end stage renal failure, transplant rejection	University of Wisconsin, Madison	Withdrawn	No outcome recorded
Phase 4	NCT02274662 Background	Aug 2014 → Aug 2023	T-cell immunodeficiency, thymus gland disorder	Sumitomo Pharma Switzerland GmbH	Completed	No outcome recorded
Phase 4	NCT02683291 Background	Jan 2014 → Jan 2015	cytomegalovirus infection, disease related to solid organ transplantation	Associação Médico Espírita de Botucatu	Completed	No outcome recorded
Phase 4	NCT01950819 Background	Dec 2013 → Feb 2017	end stage renal failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02218437 Background	Oct 2013 → Oct 2015	disease related to hematopoietic stem cell transplant	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 4	NCT02377193 Comparator	Sep 2013 → Jan 2017	transplant rejection	University Hospital, Toulouse	Completed	No outcome recorded
Phase 4	NCT01895049 Comparator	Aug 2013 → Mar 2016	cytomegalovirus infection	Helio Tedesco Silva Junior	Completed	No outcome recorded
Phase 4	NCT02084446 Background	Dec 2012 → Jul 2014	cytomegalovirus infection, disease related to solid organ transplantation	Ronaldo de Matos Esmeraldo, MD	Completed	No outcome recorded
Phase 4	NCT03377283 Comparator	Aug 2012 → Mar 2015	—	Medical University Innsbruck	Completed	No outcome recorded
Phase 4	NCT01312064 Comparator	Apr 2011 → Apr 2012	impaired renal function disease	National Taiwan University Hospital	Terminated	No outcome recorded
Phase 4	NCT00771745 Comparator	Sep 2008 → Jun 2010	transplant rejection	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT01195194 Background	Mar 2008 → Jun 2012	disease related to solid organ transplantation	Josep M Grinyo	Completed	No outcome recorded
Phase 4	NCT01046955 Comparator	Nov 2005 → Apr 2007	end stage renal failure	University of Miami	Completed	No outcome recorded
Phase 4	NCT00596947 Background	Oct 2005 → Mar 2009	—	University of Pennsylvania	Terminated	No outcome recorded
Phase 4	NCT00113269 Comparator	May 2005 → Mar 2009	—	Astellas Pharma Inc	Completed	No outcome recorded

Phase not applicable5 trials
—	NCT02936505 Background	Oct 2016 → Oct 2025 overdue	—	Vastra Gotaland Region	Active not recruiting	No outcome recorded
—	NCT02845596 Comparator	Aug 2016 → Nov 2020	acquired aplastic anemia	Michael Pulsipher	Completed	No outcome recorded
—	NCT01850108 Background	May 2013 → Nov 2023	sickle cell disease	Vanderbilt-Ingram Cancer Center	Unknown	No outcome recorded
—	NCT00859131 Comparator	Mar 2009 → Jul 2012	end stage renal failure	Medical University of South Carolina	Completed	No outcome recorded
—	NCT00709293 Comparator	Jul 2008 → May 2009	ischemic disease	University of California, Los Angeles	Withdrawn	No outcome recorded

Evidence & citations 45 cited values

Every value below carries the sentence it was read from. 266 sources stand behind the page.

Field	Value	Cited text
Known as	Thymoglobulin	“A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of...” NCT01157949 ↗ 124 “A prominent example of this class of drugs is Thymoglobulin(TMG), a purified, pasteurized gamma immune globulin, which is obtained by immunization of rabbits with human thymocytes.” NCT00714480 ↗ “At our institution, one such antibody preparation (Thymoglobulin) is used in most pediatric heart transplant recipients for 3-5 days immediately after transplantation.” NCT00709293 ↗ “Children over two years and adults undergoing a first hematopoietic stem cell transplantation will receiveThymoglobulin® as part of the conditioning.” NCT05743400 ↗ “Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.” NCT01455506 ↗ “All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).” NCT01195194 ↗ “A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulin™) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)” NCT00317798 ↗ “Two randomized groups of kidney transplant recipients will be each administered the drug Thymoglobulin according to a different dosing regimen.” NCT00906204 ↗ “ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.” NCT01566656 ↗ “The two commonly used ATGs, Thymoglobulin and ATG-F have slightly different antigen profile and antibody concentrations.” PMID 27855166 ↗ Nov 2016 “Patients receive immunosuppressive induction treatment with thymoglobulin (at least 1 dose and maximum of 5 doses)” NCT07203664 ↗ “rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)” NCT07677306 ↗ “Conditioning regimen Thymoglobulin (0.5/mg/kg à D-9, 2 mg /kg at D-8 and 2.5 mg/kg à D-7)” NCT06646497 ↗ “Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation” NCT01046955 ↗ “Thymoglobulin (Sangstat), a FDA-approved polyclonal rabbit-IgG antithymocyte preparation” NCT00062712 ↗ “Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)” NCT01572181 ↗ “Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5” NCT02776202 ↗ “Thymoglobulin® (Genzyme) \[rabbit anti-thymocyte globulin (ATG)\]” NCT03292861 ↗ “Rabbit antithymocyte globulin (rATG; thymoglobulin, Genzyme)” PMID 22544699 ↗ Apr 2012 “thymoglobulin (A :rATG ,Sang Stat,France) 2.5mg/kg/dx4d” NCT03821987 ↗ “rabbit anti-thymocyte globulin (rATG, Thymoglobulin®)” NCT05385432 ↗ “Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)” NCT03615144 ↗ “3 Thymoglobulin doses given prior to thymus tx.” NCT00579709 ↗ “ATG (thymoglobulin; Sang Stat, France)” NCT03799224 ↗ “ATG (thymoglobulin; Sang Stat, France)” NCT03793517 ↗ “Thymoglobulin 2 mg/kg IV Days -8, -7” NCT05298358 ↗ “rabbit Thymoglobulin (rATG)” NCT07607197 ↗ NCT00088543 ↗ NCT00887042 ↗ NCT04046549 ↗ NCT01556347 ↗ NCT00040651 ↗ NCT00089947 ↗ NCT02867800 ↗ NCT05735717 ↗ NCT04302805 ↗ NCT02683291 ↗ NCT00476229 ↗ NCT00475020 ↗ NCT00506948 ↗ NCT00737685 ↗ NCT00750126 ↗ NCT00771745 ↗ NCT06872333 ↗ NCT01312064 ↗ NCT00681343 ↗ NCT00806598 ↗ NCT00402558 ↗ NCT01280617 ↗ NCT00542828 ↗ NCT00006178 ↗ NCT01028092 ↗ NCT00592306 ↗ NCT02441803 ↗ NCT02137239 ↗ NCT04888741 ↗ NCT01895049 ↗ NCT02447822 ↗ NCT02512497 ↗ NCT00990249 ↗ NCT01856803 ↗ NCT00685061 ↗ NCT01471444 ↗ NCT00857389 ↗ NCT00669890 ↗ NCT00235781 ↗ NCT03088280 ↗ NCT06066255 ↗ NCT00506129 ↗ NCT03219359 ↗ NCT01354301 ↗ NCT03292861 ↗ NCT00523809 ↗ NCT07052370 ↗ NCT02084446 ↗ NCT01850108 ↗ NCT03852407 ↗ NCT02582775 ↗ NCT02745717 ↗ NCT01157949 ↗ NCT00706680 ↗ NCT01087398 ↗ NCT01622556 ↗ NCT00682292 ↗ NCT00303667 ↗ NCT00593645 ↗ NCT00545519 ↗ NCT00117689 ↗ NCT00916045 ↗ NCT03171831 ↗ NCT00970073 ↗ NCT00899431 ↗ NCT00882323 ↗ NCT00885833 ↗ NCT05743400 ↗ NCT02495077 ↗ NCT02224872 ↗ NCT01246206 ↗ NCT02544113 ↗ NCT00455013 ↗ NCT01135537 ↗ NCT00409695 ↗ NCT03006419 ↗ NCT00813124 ↗ NCT02877082 ↗ NCT02627573 ↗ NCT04903054 ↗ NCT02130817 ↗ NCT01490723 ↗ NCT01844635 ↗ NCT00709592 ↗ NCT01939171 ↗ NCT00679536 ↗ NCT00235300 ↗ NCT01172418 ↗ NCT00275509 ↗ NCT00670410 ↗ NCT01149993 ↗ NCT02464878 ↗ NCT06083129 ↗ NCT00469014 ↗ NCT02083991 ↗ NCT01392989 ↗ NCT04009525 ↗ NCT02833805 ↗
Known as	anti thymoglobulin	“Drug: anti thymoglobulin” NCT01856803 ↗
Known as	anti-human T-lymphocyte immunoglobulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03357159 ↗
Known as	Anti-human thymocyte globulin (rabbit)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00007787 ↗
Known as	Anti-lymphocyte serum	“Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)” NCT03079089 ↗
Known as	Anti-Lymphocyte-Globulin	“ATG FRESENIUS (Anti-Lymphocyte-Globulin)” NCT00678275 ↗
Known as	Anti-T-Lymphocyte Globulin	“Anti-T-Lymphocyte Globulin (ATG)” NCT00733733 ↗
Known as	Anti-Thymocyte Globin (ATG)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01106157 ↗
Known as	Anti-Thymocyte Globulin (Rabbit)	“Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme” NCT00915811 ↗ 22 “Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)” NCT03615144 ↗ “Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]” NCT00088543 ↗ “Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]” NCT00089947 ↗ NCT02790515 ↗ NCT03597594 ↗ NCT01856257 ↗ NCT07257419 ↗ NCT03531736 ↗ NCT04066114 ↗ NCT00564538 ↗ NCT00260689 ↗ NCT04202835 ↗ NCT01790594 ↗ NCT01621477 ↗ NCT01217723 ↗ NCT04224558 ↗ NCT02188719 ↗ NCT00566696 ↗ NCT01810588 ↗ NCT04395222 ↗ NCT01050764 ↗ NCT03600909 ↗
Known as	anti-thymocyte globulin (rabbit), thymoglobulin	“anti-thymocyte globulin (rabbit), thymoglobulin” NCT00771745 ↗
Known as	Anti-thymocyte globulines	“Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)” NCT01572181 ↗
Known as	Anti-thymoglobulin, rabbit (ATG, rabbit ATG)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00186628 ↗
Known as	antithymocyte globulin	“reduced intensity preparative regimen that included fludarabine, cyclophosphamide and antithymocyte globulin, allowed engraftment of donor stem cells in subjects with SAA” NCT01129323 ↗ 7 “Rabbit antithymocyte globulin (rATG, Thymoglobulin®) is the most common induction immunosuppression therapy in kidney transplantation.” PMID 26285695 ↗ Aug 2015 “assessing the efficacy and safety of antithymocyte globulin (ATG-Fresenius) plus tacrolimus monotherapy at gradually decreasing doses.” PMID 20883560 ↗ Oct 2010 “comparing antithymocyte globulin (Thymoglobulin) (group A, N=43) versus alemtuzumab (group B, N=43) versus daclizumab (group C, N=42)” PMID 24477186 ↗ Jun 2014 “Thymoglobulin, rabbit derived antithymocyte globulin (Thymoglobulin, SangStat, Fremont, CA)” NCT00235781 ↗ “anti-thymocyte globulin (ATG) will be used to condition the recipients for transplantation” NCT00325741 ↗ “antithymocyte globulin (Thymoglobulin®, Genzyme; 5 mg/kg total dose)” PMID 36028757 ↗ Aug 2022 “Thymoglobulin (anti-thymocyte globulin)” NCT01149993 ↗
Known as	Antithymocyte Immunoglobulin (Rabbit)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04114188 ↗ 1 NCT03789006 ↗
Known as	ATG	“We initiated a prospective randomized controlled trial of polyclonal rabbit anti-T-cell globulin (ATG) in patients with type 1 diabetes within 4 weeks of diagnosis and with...” PMID 17491669 ↗ Aug 2004 15 “Determine the safety and tolerability, in terms of clinical and laboratory toxicity, of anti-thymocyte globulin (ATG) combined with sirolimus in patients with relapsed multiple myeloma.” NCT00317798 ↗ “Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3.” NCT00186823 ↗ “Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).” NCT00316810 ↗ “received rabbit anti-thymocyte globulin (ATG) 3 mg/kg on day 8 post-transplant.” PMID 34373186 ↗ Aug 2021 “rabbit anti-thymocyte globulin (ATG) (Thymoglobuline, Genzyme)” NCT01844635 ↗ “Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV” NCT04202835 ↗ “Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)” NCT00961142 ↗ “ATG FRESENIUS (Anti-Lymphocyte-Globulin)” NCT00678275 ↗ “ATG (thymoglobulin; Sang Stat, France)” NCT03799224 ↗ “Anti-T-Lymphocyte Globulin (ATG)” NCT00733733 ↗ “Thymoglobulin (ATG)” NCT00469014 ↗ “ATG” NCT01490723 ↗ NCT02218437 ↗ NCT05482542 ↗ NCT05634915 ↗
Known as	ATG (Anti-Thymocyte Globulin)	“ATG (Anti-Thymocyte Globulin)” NCT02188719 ↗
Known as	ATG (rabbit)	“ATG ( rabbit ) 2 mg / kg / d-5” NCT06769568 ↗ 4 NCT00424489 ↗ NCT01104025 ↗ NCT00278564 ↗ NCT03849651 ↗
Known as	ATG S Fresenius	“ATG S Fresenius” NCT01810926 ↗
Known as	ATG-F	“Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients...” PMID 21467544 ↗ Apr 2011 2 “The two commonly used ATGs, Thymoglobulin and ATG-F have slightly different antigen profile and antibody concentrations.” PMID 27855166 ↗ Nov 2016 NCT02523768 ↗
Known as	ATG-Fresenius	“The ATG-Fresenius® is administered by slow infusion over four hours after antihistamine (2 bulbs Polaramine® IV) and intravenous methylprednisolone (minimum 30mg); it is...” NCT02523768 ↗ 14 “Patients who fulfill the inclusion criteria and give their informed consent to participate in the study will be randomized to be treated either with a course of ATG-Fresenius...” NCT00190502 ↗ “Patients enrolled in the study will be randomized to receive ATG (Fresenius) at a dosage of either 30 mg/Kg (10 mg/Kg on days -4, -3 and -2) or 15 mg/Kg (5 mg/Kg on days -4, -3 and -2).” NCT00934557 ↗ “All patients received rATG for 4 days [ATG-Fresenius (ATG-F) 4 mg/kg/day or Thymoglobulin (Thymo-S) 1.25 mg/kg/day] plus MMF and short-term corticosteroids.” PMID 15814548 ↗ May 2005 “assessing the efficacy and safety of antithymocyte globulin (ATG-Fresenius) plus tacrolimus monotherapy at gradually decreasing doses.” PMID 20883560 ↗ Oct 2010 “Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).” NCT00316810 ↗ “treatment with ATG-Fresenius administered in addition to standard treatment” NCT01324934 ↗ “ATG-Fresenius 20 mg/kg day -4 to -2” NCT01582048 ↗ “ATG-Fresenius versus ATG” NCT03631563 ↗ NCT00934557 ↗ NCT02028416 ↗ NCT00678275 ↗ NCT02377193 ↗ NCT00861536 ↗ NCT00733733 ↗
Known as	ATG-Fresenius S	“The purpose of this study is to assess the efficacy and safety of the study drug, known as "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant...” NCT00105183 ↗ 3 “anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals)” NCT03357159 ↗ NCT01324934 ↗ NCT00655343 ↗
Known as	ATLG	“Although rabbit anti-T-lymphocyte globulin (ATLG) is largely used for the prevention of immune-mediated complications” PMID 28705454 ↗ Jul 2017 1 “anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals)” NCT03357159 ↗
Known as	EZ-2053	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00105183 ↗
Known as	Grafalon	“anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals)” NCT03357159 ↗
Known as	IMTIX-Sangstat ATG	“Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).” NCT00316810 ↗
Known as	Lapine T-Lymphocyte Immune Globulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04521946 ↗ 4 NCT04083183 ↗ NCT04530487 ↗ NCT04776850 ↗ NCT05457556 ↗
Known as	Rabbit Anti-Human T-Lymphocyte Globulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03828682 ↗ 1 NCT03393611 ↗
Known as	Rabbit Anti-Human Thymocyte Globulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00316810 ↗
Known as	rabbit anti-T-lymphocyte globulin	“Although rabbit anti-T-lymphocyte globulin (ATLG) is largely used for the prevention of immune-mediated complications” PMID 28705454 ↗ Jul 2017
Known as	Rabbit Anti-thymocyte globulin (ATG)	“Thymoglobulin® (Genzyme) \[rabbit anti-thymocyte globulin (ATG)\]” NCT03292861 ↗ 3 “Rabbit Anti-thymocyte globulin (ATG)” NCT01565616 ↗ NCT02845596 ↗ NCT05600426 ↗
Known as	Rabbit Anti-thymocyte Globulin (rATG)	“Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)” NCT00542828 ↗ 3 “rabbit antithymocyte globulin (RATG)” NCT01517984 ↗ NCT00771875 ↗ NCT04328727 ↗
Known as	rabbit anti-thymocyte immunoglobulin	“rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days” NCT06009965 ↗ 1 NCT03099122 ↗
Known as	rabbit antithymocyte globulin	“A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic...” NCT02404025 ↗ 53 “In mesenchymal stem cells (MSC) group, UC-MSCs were injected intravenously at a dose of 1 × 106/kg per week starting on the 14th day after administration of rabbit...” PMID 33639900 ↗ Feb 2021 “Rabbit anti-thymocyte globulin (rATG), a polyclonal rabbit-derived antibody that depletes lymphocytes, including T cells, was introduced to prevent GVHD and transplant rejection.” NCT05634915 ↗ “Describe the pharmacokinetics of rabbit anti-thymocyte globulin (rATG) in patients receiving allogeneic transplantation and determine the frequency of rATG antibody development” NCT00186823 ↗ “Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia.” PMID 22796534 ↗ Jul 2012 “Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.” NCT01455506 ↗ “A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulin™) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)” NCT00317798 ↗ “Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1.” NCT01049854 ↗ “Rabbit antithymocyte globulin (rATG, Thymoglobulin®) is the most common induction immunosuppression therapy in kidney transplantation.” PMID 26285695 ↗ Aug 2015 “Our previous case report has shown promising results for rabbit antithymocyte globulin (rATG) in the treatment of Graves' orbitopathy.” PMID 35615718 ↗ May 2022 “All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.” NCT01950819 ↗ “Thymoglobulin (rabbit antithymocyte globulin) is FDA approved for the treatment of acute cellular rejection.” NCT01280617 ↗ “The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.” NCT02166177 ↗ “rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)” NCT07677306 ↗ “All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin.” NCT00849888 ↗ “received rabbit anti-thymocyte globulin (ATG) 3 mg/kg on day 8 post-transplant.” PMID 34373186 ↗ Aug 2021 “induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®)” NCT01517984 ↗ “Cyclophosphamide (200 mg /kg) / rabbit antithymocyte globulin (6.0 mg/kg)” NCT05482542 ↗ “rabbit antithymocyte globulin (2 × 1.5 mg/kg, postoperative days 0 and 1)” PMID 37525369 ↗ Aug 2023 “rabbit anti-thymocyte globulin (ATG) (Thymoglobuline, Genzyme)” NCT01844635 ↗ “rabbit anti-thymocyte globulin (rATG, Thymoglobulin®)” NCT05385432 ↗ “rabbit anti-thymocyte globulin (rATG)” NCT05525507 ↗ “Rabbit Anti-thymocyte globulin (ATG)” NCT01565616 ↗ NCT00579527 ↗ NCT01729494 ↗ NCT03980769 ↗ NCT04547049 ↗ NCT00113269 ↗ NCT05199103 ↗ NCT00859131 ↗ NCT01994824 ↗ NCT00556933 ↗ NCT02080195 ↗ NCT07412470 ↗ NCT02472392 ↗ NCT01019876 ↗ NCT00943800 ↗ NCT07508787 ↗ NCT00448357 ↗ NCT03663335 ↗ NCT00471848 ↗ NCT04849533 ↗ NCT00596947 ↗ NCT04688021 ↗ NCT03249831 ↗ NCT00782821 ↗ NCT00801931 ↗ NCT02274662 ↗ NCT03377283 ↗ NCT06158828 ↗ NCT05385432 ↗ NCT02936505 ↗ NCT00899847 ↗ NCT00230035 ↗
Known as	rabbit Thymoglobulin (r-ATG)	“rabbit Thymoglobulin (r-ATG)” NCT02084446 ↗
Known as	rabbitATG	“The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2.” NCT00679536 ↗ 21 “Patients will receive rabbit ATG 2.5 mg/kg on Day -2 and -1 (total 5 mg/kg)” NCT07570745 ↗ “rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation” NCT00325741 ↗ “alemtuzumab will be replaced with rabbit ATG on days -10 through -7” NCT02165007 ↗ “rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2” NCT01461837 ↗ NCT05214066 ↗ NCT01745913 ↗ NCT05293509 ↗ NCT02784561 ↗ NCT05736419 ↗ NCT02143830 ↗ NCT03263559 ↗ NCT02404025 ↗ NCT00038857 ↗ NCT02916979 ↗ NCT06412497 ↗ NCT02838992 ↗ NCT02203396 ↗ NCT00593554 ↗ NCT01129323 ↗ NCT02828592 ↗ NCT01530555 ↗
Known as	rATG	“Within 3 weeks of the apheresis stem cell collection, the first group's participants will be admitted to the hospital and will undergo a five-day conditioning regimen...” NCT00230035 ↗ 19 “All patients received either rabbit antithymocyte globulin (rATG) or interleukin 2 receptor antagonists (IL-2RA) in addition to tacrolimus (FK), mycophenolate mofetil (MMF),...” PMID 25557762 ↗ Jan 2015 “Rabbit anti-thymocyte globulin (rATG), a polyclonal rabbit-derived antibody that depletes lymphocytes, including T cells, was introduced to prevent GVHD and transplant rejection.” NCT05634915 ↗ “Describe the pharmacokinetics of rabbit anti-thymocyte globulin (rATG) in patients receiving allogeneic transplantation and determine the frequency of rATG antibody development” NCT00186823 ↗ “The first investigational conditioning regimen is cyclophosphamide (chemotherapy) and rATG (rabbit anti-thymocyte globulin, a protein against immune cells).” NCT05482542 ↗ “A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulin™) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)” NCT00317798 ↗ “HPSC infusion will be preceded by a conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG).” NCT05525507 ↗ “Rabbit antithymocyte globulin (rATG, Thymoglobulin®) is the most common induction immunosuppression therapy in kidney transplantation.” PMID 26285695 ↗ Aug 2015 “Our previous case report has shown promising results for rabbit antithymocyte globulin (rATG) in the treatment of Graves' orbitopathy.” PMID 35615718 ↗ May 2022 “The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.” NCT02166177 ↗ “rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days” NCT06009965 ↗ “Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)” NCT00943800 ↗ “Rabbit antithymocyte globulin (rATG; thymoglobulin, Genzyme)” PMID 22544699 ↗ Apr 2012 “organ perfusion with rabbit anti-thymocyte globulin (rATG)” NCT03377283 ↗ “Induction therapy: rabbit anti-thymocyte globulin (rATG)” NCT03663335 ↗ “thymoglobulin (A :rATG ,Sang Stat,France) 2.5mg/kg/dx4d” NCT03821987 ↗ “rabbit anti-thymocyte globulin (rATG, Thymoglobulin®)” NCT05385432 ↗ “rATG 1.5 mg/kg/dose IV is given from day -4 to -1.” NCT01129323 ↗ “r-ATG (Anti-thymocyte globulin (rabbit))” NCT00260689 ↗ “rabbit Thymoglobulin (rATG)” NCT07607197 ↗
Known as	rATG (rabbit antithymocyte globulin)	“rATG (rabbit antithymocyte globulin)” NCT01172418 ↗
Known as	Sang Stat	“thymoglobulin (A :rATG ,Sang Stat,France) 2.5mg/kg/dx4d” NCT03821987 ↗
Known as	Thymo-S	“All patients received rATG for 4 days [ATG-Fresenius (ATG-F) 4 mg/kg/day or Thymoglobulin (Thymo-S) 1.25 mg/kg/day] plus MMF and short-term corticosteroids.” PMID 15814548 ↗ May 2005
Known as	Thymoglobulin, Genzyme	“Thymoglobulin, Genzyme” NCT00682292 ↗
Known as	Thymoglobuline	“Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2.” NCT01145976 ↗ 13 “Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2.” NCT00774527 ↗ “Flu-Bu-ATG (Study A) associated Fludarabine (30mg/m²/5 days), Oral Busulfan (8 mg/kg over 2 days) and Thymoglobuline (2.5 mg/m²/1day).” NCT00894049 ↗ “ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2.” NCT05214066 ↗ “associating Fludarabine, Thymoglobuline, and intravenous Busulfan with adapted dose” NCT02483325 ↗ “Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)” NCT03035422 ↗ “Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)” NCT03079089 ↗ “rabbit anti-thymocyte globulin (ATG) (Thymoglobuline, Genzyme)” NCT01844635 ↗ “rabbit antithymocyte globulin (ATG, Thymoglobuline®)” NCT01530555 ↗ NCT00961142 ↗ NCT00841724 ↗ NCT01572181 ↗ NCT00130754 ↗ NCT00915811 ↗
Known as	TMG	“A prominent example of this class of drugs is Thymoglobulin(TMG), a purified, pasteurized gamma immune globulin, which is obtained by immunization of rabbits with human thymocytes.” NCT00714480 ↗
Action	Deplete	“thymoglobulin to kill the T-cells” NCT00040651 ↗
Modality	Protein / enzyme biologic	“a FDA-approved polyclonal rabbit-IgG antithymocyte preparation” NCT00006178 ↗
Route	Intravenous	“Thymoglobulin will be given intravenously” NCT00006178 ↗